ferumoxytol (Rx)

Brand and Other Names:Feraheme
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 510mg/17mL vial (30mg/mL)
  • Concentration expressed in terms of elemental Fe
more...

Iron Deficiency Anemia

Indicated for iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron

Also, indicated for IDA in adults who have chronic kidney disease (CKD)

510 mg IV infused over 15 min once, followed by a second dose 3-8 days later

Also see Administration

MRI of Brain Tumors (Orphan)

For use in MR imaging for the management of brain tumors

Orphan indication sponsor

  • Oregon Health & Science University; 3181 SW Sam Jackson Pk Road, Mailcode L603; Portland, OR 97239

Dosage Modifications

Renal impairment

  • Hemodialysis
    • Administer dose once blood pressure stable and patient has completed at least 1 hr of hemodialysis
    • Monitor for hypotension
    • Not removed by hemodialysis; dose adjustment not necessary

<18 years: Safety and efficacy not established

Next:

Adverse Effects

1-10%

Headache (1.8-3.4%)

Nausea (1.8-3.1%)

Dizziness (1.5-2.6%)

Hypotension (2.5%)

Peripheral edema (2%)

Edema (1.5%)

Vomiting (1.5%)

Fatigue (1.5%)

Abdominal pain (1.3%)

Chest pain (1.3%)

Cough (1.3%)

Pruritus (1.2%)

Pyrexia (1%)

Diarrhea (1%)

Back pain (1%)

Muscle spasms (1%)

Dyspnea (1%)

Rash (1%)

<1%

Hypotension (0.4%)

Chest pain (0.2-0.3%)

Arthralgia (0.3%)

Dyspnea (0.3%)

Flushing (0.2%)

Chest discomfort (0.2%)

Nausea (0.2%)

Back pain (0.2%)

Dizziness (0.2%)

Headache (0.2%)

Frequency Not Defined

Life-threatening anaphylactic/anaphylactoid reactions

Cardiac/cardiorespiratory arrest

Clinically significant hypotension

Loss of consciousness

Unresponsiveness

Tachycardia/rhythm abnormalities

Angioedema

Ischemic myocardial events

Congestive heart failure

Pulse absent

Cyanosis

Syncope

Postmarketing Reports

Fatal, life-threatening, and serious anaphylactic-type reactions

Cardiac/cardiorespiratory arrest

Clinically significant hypotension

Syncope

Unresponsiveness

Loss of consciousness

Tachycardia/rhythm abnormalities

Angioedema

Ischemic myocardial events

Congestive heart failure

Absent pulse

Cyanosis

Previous
Next:

Warnings

Black Box Warnings

Serious hypersensitivity/ anaphylaxis reactions

  • Fatal and serious hypersensitivity reactions including anaphylaxis have occurred
  • Initial symptoms may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest
  • Only administer as IV infusion over at least 15 minutes when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions
  • Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following infusion, including monitoring of blood pressure and pulse during and after administration
  • Hypersensitivity reactions have occurred in patients in whom a previous dose was tolerated

Contraindications

Known hypersensitivity to ferumoxytol or any of its components

History of allergic reaction to any intravenous iron product

Cautions

May cause life-threatening hypersensitivity reactions such as anaphylaxis and/or anaphylactoid reactions (see Black Box Warnings)

Elderly patients (>65 years) or patients with multiple comorbidities who experience a serious hypersensitivity reaction due to ferumoxytol may have more severe outcomes

Risk of anaphylaxis increases in patients with multiple drug allergies

Anaphylactic reactions presenting with cardiac/cardiorespiratory arrest, syncope, hypotension and unresponsiveness have been identified in post-marketing reports

Clinically significant hypotension may occur; in a clinical study with ferumoxytol in patients with IDA, regardless of etiology, moderate hypotension was reported in 0.2% (2/997) of subjects

Excessive therapy with IV iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis; monitor the hematologic response during IV iron therapy; do not administer ferumoxytol to patients with iron overload; within 24 hr following administration, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring iron in the ferumoxytol

Monitor hematologic responses during therapy, do not administer if evidence of iron overload

Can alter magnetic resonance imaging (MRI) studies

Previous
Next:

Pregnancy & Lactation

Pregnancy

Limited available data with ferumoxytol use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes

In animal studies, ferumoxytol to pregnant rabbits during organogenesis caused adverse developmental outcomes including fetal malformations and decreased fetal weights at maternally toxic doses of 6 times the estimated human daily dose

Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as postpartum anemia

Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight

Lactation

There are no data on the presence of ferumoxytol in human milk, the effects on the breastfed child, or the effects on milk production

Ferumoxytol has been detected in the milk of lactating rats

Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ferumoxytol and any potential adverse effects on the breastfed child from ferumoxytol or from the underlying maternal condition

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Iron-carbohydrate complex released within macrophage vesicles; either enters intracellular iron storage (eg, ferritin) or transferred to plasma transferrin for transport to erythroid precursor cells for hemoglobin incorporation

Absorption

Peak plasma concentration: 206 mcg/mL

Peak plasma time: 0.32 hr

Distribution

Vd: 3.16 L (two 510 mg-dose administered IV within 24 hr)

Excretion

Half-life: 15 hr

Clearance: 3.16 L

Previous
Next:

Administration

IV Compatibility

0.9% NaCl

D5W

IV Preparation

Dilute dose in 50-200 mL 0.9% NaCl or D5W

Inspect visually for particulate matter and discoloration prior to administration

IV Administration

Should only be administered as a diluted IV infusion over a minimum period of 15 minutes

Administer while the patient is in a reclined or semi-reclined position

Allow at least 30 minutes between administration of ferumoxytol and administration of other medications that could potentially cause serious hypersensitivity reactions and/or hypotension (eg, chemotherapeutic agents, monoclonal antibodies)

Diluted solutions immediately but may be stored at controlled room temperature (25°C) for up to 4 hours or refrigerated (2-8°C) for up to 48 hours

Storage

Unused vials: Store at room temperature (20-25°C [68-77°F]); excursions permitted to 15-30°C (5-86°F)

Diluted solutions: Stored at room temperature (25°C) for up to 4 hr or refrigerated (2-8°C) for up to 48 hr

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous